Trial
NCT03259334
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Shire
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Ontamalimab
Why stopped
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-14